Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Potential of selected Lamiaceae plants in anti(retro)viral therapy

Maja Bekut a, *, Snežana Brkić b, c, Nebojša Kladar a, Gordana Dragović d, Neda Gavarić a, Biljana Božin a

a University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Hajdučka Veljkova 3, 21000 Novi Sad, Serbia
b University of Novi Sad, Faculty of Medicine, Department of Infectious Diseases, Hajdučka Veljkova 3, 21000 Novi Sad, Serbia
c Clinical Centre of Vojvodina, Clinic for Infectious Diseases, Hajdučka Veljkova 1, 21000 Novi Sad, Serbia
d University of Belgrade, School of Medicine, Department of Pharmacology, Clinical Pharmacology and Toxicology, Dr Subotica 1/III, 11000 Belgrade, Serbia

A R T I C L E   I N F O

Article history:
Received 17 August 2017
Received in revised form 17 November 2017
Accepted 15 December 2017
Available online 16 December 2017

Keywords:
Lamiaceae
Herbs
Antiviral
Antiretroviral
Anti-HIV

A B S T R A C T

Constant search for new drugs with antiviral properties often extends to products of natural origin. Lamiaceae is one of the most important herbal families, well known for various biological and medicinal effects of a variety of aromatic spices, including thyme, mint, oregano, basil, sage, savory, rosemary, self-heal, hyssop, lemon balm and many others. The paper provides a review of antiviral potential of previously mentioned plants which has been demonstrated so far, with special emphasis on anti-HIV properties. Relevant articles were compiled by searching plant names combined with keywords describing antiviral activity. The antiviral effect is direct, with prominent activity against enveloped viral species. Initial stages of the viral life cycle are the most affected, as these plants appear to be targeting mainly viral structures responsible for attachment to target cells. In case of HIV, there is some activity against key enzymes in the viral life cycle. Even in the case of drug resistance, there is an equal susceptibility to applied herbal preparations. Some in vivo experiments suggest that use of Lamiaceae representatives could help in prevention and treatment of some viral diseases. A possible reduction of side effects of diseases and conventional drug therapy are also some aspects worth further investigations.

© 2017 Elsevier Ltd. All rights reserved.

Contents

1. Introduction .................................................................................................................................................. 302
2. Lamiaceae family ............................................................................................................................................. 302
3. Anti(retro)viral properties of Lamiaceae .................................................................................................. 302
4. Natural products and considerations of adequate form ........................................................................... 302
5. Active compounds in plants ....................................................................................................................... 303
   5.1. Compounds with anti-HIV activity .................................................................................................... 303
   5.2. Compounds with activity against other viruses .............................................................................. 308
6. Activity versus toxicity ............................................................................................................................... 308
7. Studying mechanism of antiviral activity .................................................................................................. 309
   7.1. Time-of-addition (T-o-A) studies ...................................................................................................... 309
   7.2. Comparison with conventional drugs ............................................................................................... 311
8. Studying activity in cases of chronic HIV infection .................................................................................... 311
9. Potential position in the therapy ................................................................................................................ 311
10. The “non- in vitro” studies and future considerations ................................................................................ 311
11. Conclusions ................................................................................................................................................ 312
    Conflicts of interest .................................................................................................................................... 312
    Acknowledgements .................................................................................................................................... 312
    References .................................................................................................................................................. 312

* Corresponding author.
E-mail address: maja.bekut@mf.uns.ac.rs (M. Bekut).

https://doi.org/10.1016/j.phrs.2017.12.016
1043-6618/© 2017 Elsevier Ltd. All rights reserved.
1. Introduction

Modern therapy of human immunodeficiency virus (HIV) infections and acquired immunodeficiency syndrome (AIDS) is called combined antiretroviral therapy (cART). As the name suggests, the therapy combines at least three drugs from which at least two are classified in different groups (Table 1) based on their mechanism of activity (M-o-A) [1].

Unfortunately, cART is associated with numerous and various adverse effects in patients, ranging from mild to life-threatening [2]. Furthermore, resistance to almost all groups of drugs could occur in both HIV-1 and HIV-2 [3]. Finally, the therapy is not available to everyone, reaching an estimated 46% of infected people [4]. Bearing all of that in mind, it is clear why a constant search for safe, efficient and cheap drugs with significant anti-HIV effects is required.

So far, numerous studies have been conducted in order to evaluate antiviral properties of mainly medicinal and aromatic herbs, but also plants not used in traditional medicine [5]. Different plant-based products and isolated compounds of natural origin exhibited antiviral effects against various viruses, including HIV [6]. Different classes of bioactive compounds from plants, including flavonoids, coumarins, polyphenols, tannins, terpenoids, essential oils, alkaloids, polysaccharides and proteins were tested and proven to be active against a wide range of viral species [7].

The use of medicinal plants has numerous advantages. It was determined that HIV patients who opt for herbal treatment along side the conventional one have lower mortality, longer life expectancy and better life quality than the patients using only conventional therapy [8,9]. Plants also have the potential to reduce the harmful effects of drugs [10]. Furthermore, there are some reports of case studies of people using only plants as therapy for HIV, who managed to keep the viral load undetectable during or after applied phytotherapy [11,12]. Although plants and compounds discovered so far cannot replace conventional drugs, these reports provide a starting point for further examination of activity of some plants and their possible application in adjunctive therapy.

However, there are not many published papers that comprehensively present the data related to antiretroviral effects of particular groups of plants. Therefore, in this paper, the results of conducted studies on antiviral properties of selected genera and species of Lamiaceae family are summarized. The focus is set specifically on anti-HIV properties with possible or confirmed M-o-A, but the activities against other viruses are also described, with the purpose of providing supplementary data on antiviral properties.

Relevant articles were searched for through the PubMed database and Google Scholar, by using a combination of Latin or English names of selected plants with words “antiviral”, “antiretroviral”, “anti-HIV”, “HIV” and “antimicrobial”. The content of discovered articles was evaluated to determine their suitability for our topic. Afterwards, the references of the selected articles were examined for additional relevant literature. Only articles in the English language, with full text available were included.

2. Lamiaceae family

Lamiaceae (Labiatae) plant family is the sixth largest plant family, with >200 genera and >7000 species. Plants belonging to this family are dispersed worldwide and considered as some of the least difficult plants to cultivate. Coupled with easiness of cultivation, their aromatic, spicy properties make them an important part of pharmaceutical, food and cosmetic industries [13]. Plants discussed in this paper are herbaceous, so the parts most frequently used are leaves and herba, upper parts of the segment of the plant, mostly collected in full blossom. They can be used as fresh or dried material (as it is the case in culinary and food industries), but also in dosage forms specially prepared for external and internal use. Traditional forms of application for medicinal purposes include infusum (commonly called tea- form obtained by pouring nearly boiling water over the plant material), syrup, tincture, gargle (mouthwash), drops and many others. Besides drinking and using as mouthwash, these forms can be applied by rubbing and inhaling as well [14–16]. Some of the mainly used Lamiaceae plants are presented in Table 2. Beside their traditional use, many of them are also accepted in conventional medicine. For this reason, the World Health Organization suggests that plants such as some Lamiaceae family representatives, with a long history of use and confirmed therapeutic effects should be further evaluated for new activities and properties that could be useful in treatment and prevention of different diseases [17].

Different plants belonging to this family are classified into two subfamilies based on the presence of rosmarinic acid (Nepetoideae) or iridoids (Lamioidae). However, both of the plant groups of plants have various levels of essential oil (EO), with higher percent usually found in Nepetoideae subfamily [37,38]. Plants from this family are well known for their antibacterial, antifungal and antidepressant properties [39–42] and are used for extraction and isolation of a wide range of bioactive compounds [43–45]. This review included ten genera of Lamiaceae family, which are, to the best of our knowledge, the most widely known representatives, with distribution all over the world and a well-established tradition of use.

3. Anti(retro)viral properties of Lamiaceae

Antiviral effects of Lamiaceae plants have mainly been proven in vitro, with some effects also having been confirmed in other types of experiments, such as indirect effects in healthy volunteers, or in patients. The main findings are displayed in Table 3 - activity against HIV and Table 4 - activity against other viruses. The activity against HIV in Table 3 refers to HIV-1, unless otherwise stated.

4. Natural products and considerations of adequate form

An investigated substance (IS) can be:

1. a plant extract obtained by using different solvents e.g. aqueous (AE), ethanolic (EE), methanolic (ME), ethyl acetate (EAE), etc.,
2. an EO isolated from raw plant material mainly by hydro- or steam distillation and
3. a single chemical compound, either of natural origin or (semi)synthesized.

The majority of tested plants were prepared in the form of AE. This type of extraction is probably the simplest for preparation, as it resembles the preparation of previously mentioned infusum (tea) which is used traditionally and convenient for use at patient’s home [95]. Two other frequent types of extracts are EE and EO. The first type, EE can also be prepared at home (e.g. by macerating fresh or dried plants with diluted ethanol); and while ethanol can enhance the extraction of active compounds, higher concentrations of ethanol can show interactions with antiretroviral and other drugs. On the other hand, EOs are available as commercial products, and can be bought at different stores. Of course, only adequate application of EOs in patients (e.g. diluted in a lipid carrier) will prevent possible direct toxicity and allergic reactions [96]. Other types of extracts, obtained by using different solvents (e.g. chloroform, hexane…) have not been used for assessment of anti(retro)viral properties, probably due to their toxicity.
It is interesting to notice that conducted researches drew a comparison between several extracts. Yamasaki et al. [46] compared AE and EE for several plants, generally proving AE as more active against HIV. Other research generally supports this claim. In the case of self-heal, AE was also found to be superior in comparison to EE [56], while EAE exhibited no effects [55]. The latter paper also provided proof that AE can be absorbed from the intestine into blood, further giving potential for in vivo activity [55]. All of these data suggest that AEs are the most interesting types of extracts, which should be further studied for potential application in patients.

5. Active compounds in plants

Usually, the first step in investigating of complex natural products’ biological activity (including antiviral) is to determine the most abundant compound in any type of extract. Several of revised papers had this approach, and detection of some compounds led to further investigation of their activity against viruses.

5.1. Compounds with anti-HIV activity

Out of all of the compounds found in rosemary, only carnosol (Fig. 1) exhibited inhibition of HIV replication with acceptable toxicity [51]. A chemical analysis of hyssop AE indicated a high concentration of caffeic acid (Fig. 1) whose anti-HIV activity was later confirmed [61] and further investigation led to discovery of substituted polysaccharide, named MAR-10, another substance from hyssop with notable in vitro anti-HIV activity [97]. This is not the only polysaccharide with detected anti-HIV properties. Investigating inflorescence of self-heal, researchers were able to isolate sulfated polysaccharide named prunellin, with excellent activity against HIV, without detected cytotoxicity [54,98]. Furthermore, various active compounds were isolated from different

---

It is interesting to notice that conducted researches drew a comparison between several extracts. Yamasaki et al. [46] compared AE and EE for several plants, generally proving AE as more active against HIV. Other research generally supports this claim. In the case of self-heal, AE was also found to be superior in comparison to EE [56], while EAE exhibited no effects [55]. The latter paper also provided proof that AE can be absorbed from the intestine into blood, further giving potential for in vivo activity [55]. All of these data suggest that AEs are the most interesting types of extracts, which should be further studied for potential application in patients.

5. Active compounds in plants

Usually, the first step in investigating of complex natural products’ biological activity (including antiviral) is to determine the most abundant compound in any type of extract. Several of revised papers had this approach, and detection of some compounds led to further investigation of their activity against viruses.

5.1. Compounds with anti-HIV activity

Out of all of the compounds found in rosemary, only carnosol (Fig. 1) exhibited inhibition of HIV replication with acceptable toxicity [51]. A chemical analysis of hyssop AE indicated a high concentration of caffeic acid (Fig. 1) whose anti-HIV activity was later confirmed [61] and further investigation led to discovery of substituted polysaccharide, named MAR-10, another substance from hyssop with notable in vitro anti-HIV activity [97]. This is not the only polysaccharide with detected anti-HIV properties. Investigating inflorescence of self-heal, researchers were able to isolate sulfated polysaccharide named prunellin, with excellent activity against HIV, without detected cytotoxicity [54,98]. Furthermore, various active compounds were isolated from different

---

Table 1

| Name of the group | Mechanism of activity (M-o-A) | Some representatives of the drug group |
|-------------------|-------------------------------|--------------------------------------|
| 1.                | nucleoside-analog reverse transcriptase inhibitors (NRTIs)-analogues of nucleoside substrates | drugs targeting reverse transcriptase (RT) of HIV via active site needed for transcription of RNA into DNA | abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, zidovudine, tenofovir |
| 2.                | non-nucleoside reverse transcriptase inhibitors (NNRTIs) | drugs targeting RT via allosteric modifications of a selected group of enzymes (affecting HIV-1, and not affecting HIV-2) | etravirine, delavirdine, efavirenz, nevirapine |
| 3.                | integrase inhibitors (IIs) | drugs targeting integrase, the enzyme responsible for integration of viral DNA into host DNA | raltegravir, elvitegravir |
| 4.                | protease inhibitors (PIs) | the target is an enzyme responsible for virion maturation | amprinavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir |
| 5.                | fusion inhibitors (FIs) | inhibitors of six helix bundle of gp41, a subunit of protein responsible for fusion of HIV particles with host cells | enfuvirtide |
| 6.                | co-receptor antagonists | drugs targeting interaction of HIV gp120 and chemokine receptors via allosteric modification | maraviroc |

Table 2

Some of the Lamiaceae plants discussed in the paper and their use in traditional and conventional medicine.

| Latin name | Common name | Some of traditional uses | Reference | Use in conventional medicine, approved by relevant institutions | Reference |
|------------|-------------|--------------------------|-----------|------------------------------------------------------------|-----------|
| *Thymus vulgaris* | garden thyme | antiseptic, carminative, eupeptic | [18] | bronchoantispasmodic, expectorant, antibacterial antimicrobial | [19,20,21] |
| *Thymus serpyllum* | wild thyme | antiseptic, spasmyloptic, carminative, expectorant, sedative | [15] | antispasmodic, carminative, cholagogue, secretolytic, eupeptic (internally), cooling agent for myalgia and headache (externally) | [19,23,24] |
| *Mentha × piperita* | peppermint | eueptic, cholagogue, carminative, spasmyloptic | [22] | antispasmodic (internally), in rheumatic diseases and circulatory problems (externally) | [19,25,26] |
| *Rosmarinus officinalis* | rosemary | cholagogue, eupeptic, irritant, food additive | [16] | sedative, hypnotic, carminative (internally), symptomatic treatment of herpes labialis (externally) | [19,24,28] |
| *Melissa officinalis* | lemon balm | mild sedative, cholagogue, carminative | [27] | – | – |
| *Origanum vulgare* | oregano | antiparasitic, antihelminthic, cholagogue, carminative, spasmyloptic | [29] | antispasmodic (internally), relief of irritated skin around nostrils (externally) | [30] |
| *Origanum majorana* | marjoram | – | [31] | – | – |
| *Ocimum basilicum* | sweet basil | spasmyloptic, eupeptic, carminative antifebrile, immunoregulator, anti-inflammatory, treatment of breast disorders | [32] | – | – |
| *Prunella vulgaris* | self-heal | – | [33] | – | – |
| *Hysopus officinalis* | hyssop | antiseptic, expectorant | [34] | eueptic, inhibition of excessive perspiration (internally), antibacterial, virustatic, astringent (externally) | [19,35] |
| *Salvia officinalis* | common sage | antiseptic, astringent, gastroprotective, anti-inflammatory, spasmyloptic | [35] | – | – |
| *Satureja hortensis* | summer savory | antiseptic, eupeptic, spasmyloptic | [36] | – | – |
| *Satureja montana* | winter savory | – | – | – | – |

- Data not found in revised literature.
| Plant species | Type of extract | EC (µg/ml) | SI | Additional comments | References |
|---------------|-----------------|------------|----|---------------------|------------|
| Thymus sp.    |                 |            |    |                     |            |
| T. quinquecostatus | AE  | 31         | 4  | activity in co-cultures of cells | [46]       |
| T. serpyllum  | AE              | 31         | 4  | activity in co-cultures of cells | [46]       |
| T. vulgaris   | ME              | >500       | <3.00 | weak activity against RT | [46]       |
| T. daenensis subspecies daenensis | ME | 300         | 5.26 | ME of plant's root increased PBMC and reduced CD4 receptor density | [47]       |
| T. daenensis subspecies lancifolius | ME | >500         | <3.16 |                      | [47]       |
| T. kotschyanus | ME              | >500       | <3.18 |                      | [47]       |
| T. carmanicus | ME              | >500       | <3.11 |                      | [47]       |
| Mentha sp.    |                 |            |    |                     |            |
| Mentha × piperita var. citrata | AE | 16         | 16 | activity in co-cultures of cells | [46]       |
| Mentha × piperita s.l. “grapefruit mint” | AE | 16         | 8  | activity in co-cultures of cells | [46]       |
| Mentha × piperita | AE | 62         | 4  | activity in both in vitro and ex vivo cell lines, without noticed toxicity | [46]       |
| M. spicata    | EE              | 125        | 2  | activity in co-cultures of cells | [46]       |
| M. pulegium   | AE              | 62         | 2  | weak activity against RT | [46]       |
| M. suaveolens | EE              | 125        | 4  |                      | [46]       |
| M. haplocalyx | AE              | 250        | 4  |                      | [46]       |
| M. haplocalyx | EE              | 62         | 4  |                      | [46]       |
| Rosmarinus sp. |                 |            |    |                     |            |
| R. officinalis | AE              | 62         | 4  |                      | [46]       |
| R. officinalis | EE              | 250        | 2  |                      | [46]       |
| R. officinalis | EE              | –          | –  | extract was found to be relatively non toxic, but there was a lack of significant effect against HIV | [50]       |
| R. officinalis | EE              | –          | –  | extract was found to be toxic | [51]       |
| Melissa sp.   |                 |            |    |                     |            |
| Melissa × officinalis | AE | 16         | 4  | activity in co-cultures of cells | [46]       |
| Melissa × officinalis | AE | –          | –  | activity in both in vitro and ex vivo cell lines, without noticed toxicity | [48]       |
| Melissa × officinalis | AE | –          | –  | activity against both enfuvirtide susceptible and resistant strains | [48]       |
| Origanum sp.  |                 |            |    |                     |            |
| O. majorana   | AE              | 31         | 8  | activity in co-cultures of cells | [46]       |
| O. vulgare    | AE              | 31         | 8  | weak activity against RT | [46]       |
| Ocimum sp.    |                 |            |    |                     |            |
| O. basilicum  | AE              | 31         | 4  | activity in co-cultures of cells | [46]       |
| O. basilicum cultivar "cinnamon" | EE | 125         | >8 | activity in co-cultures of cells | [46]       |
| O. basilicum cultivar "cinnamon" | EE | 16         | 8  | potent activity against RT | [46]       |
| O. basilicum cultivar "cinnamon" | EE | 1000       | >1 |                      | [46]       |
| Plant species          | Type of extract | EC (μg/ml) | SI  | Additional comments                                                                 | References       |
|-----------------------|-----------------|------------|-----|-------------------------------------------------------------------------------------|------------------|
| *O. gratissimum*      | AE              | 10         | 110 | • activity in co-cultures of cells  
|                       |                 |            |     | • activity against RT and proviral DNA copying  
|                       |                 |            |     | • activity against HIV-2 (EC₅₀ = 75 μg/ml, SI = 14.7)                              | [52]             |
| *Prunella sp.*        |                 |            |     |                                                                                     |                  |
| *P. vulgaris*         | AE              | –          | –   | • several researches demonstrated inhibition of HIV replication, without exhibited toxicity  
|                       |                 |            |     | • concentrations displaying activity varied in wide range, approx. 1–68 μg/ml          | [46,53–57]       |
|                       | AE              | –          | –   | • activity in co-cultures of cells                                                 | [46,54,55,57]    |
|                       | AE              | –          | –   | • inhibition of interaction between HIV gp120 and target CD4 receptor               | [54,58]          |
|                       | AE              | –          | –   | • activity against RT                                                               | [46,58]          |
|                       | AE              | –          | –   | • dose-dependent activity against RT in non-competitive manner                      | [55]             |
|                       | AE              | –          | –   | • potent activity against HIV protease                                              | [49]             |
|                       | AE              | –          | –   | • moderate activity against HIV integrase                                            | [59]             |
|                       | AE              | –          | –   | • potent activity against gp41 six-helix bundle formation                           | [60]             |
|                       | EE              | –          | –   | • less potent than AE                                                                | [56]             |
|                       | EE              | –          | –   | • CXCR4 and CCR5 chemokine co-receptors were down-regulated both in vitro and in vivo in healthy volunteers | [57]             |
|                       | ME              | –          | –   | • weak activity against HIV protease                                                | [49]             |
|                       | EAE             | –          | –   | • lack of activity                                                                  | [55]             |
| *Hyssopus sp.*        |                 |            |     |                                                                                     |                  |
| *H. officinalis*      | AE              | –          | –   | • several dilutions of crude extract displayed good to high activity, without noticed toxicity  
|                       |                 |            |     | • several sub-fractions also displayed anti-HIV activity                             | [61]             |
|                       | EE              | –          | –   | • extract was found to be relatively non toxic, but there was a lack of significant effect against HIV | [50]             |
| *Salvia sp.*          |                 |            |     |                                                                                     |                  |
| *S. officinalis*      | AE              | 62         | 4   | • activity against HIV-1, both in vitro and ex vivo                                 | [46]             |
|                       | AE              | –          | –   | • activity in both in vitro and ex vivo cell lines, without noticed toxicity        | [48]             |
| *S. elegans*          | AE              | 31         | 2   | • activity in co-cultures of cells                                                | [46]             |
|                       | S. sclarea      | EE         | 31  | 2   | • inhibition of interaction between HIV gp120 and target CD4 receptor               | [46]             |
|                       | S. miltiorrhiza | AE         | 250 | 2   | • weak activity against RT                                                          | [58]             |
|                       | EE              | –          | –   | • CCR5 chemokine co-receptors were down-regulated                                  | [57]             |
| *Satureja sp.*        |                 |            |     |                                                                                     |                  |
| *S. hortensis*        | AE              | 62         | 1   | • activity in co-cultures of cells                                                | [46]             |
| *S. montana*          | AE              | 16         | 4   | • potent activity against RT                                                        | [46]             |
|                       |                 |            |     | • activity against ex vivo                                                          |                  |

- Assay was not conducted/not applicable.
EC- effective concentration, which displays activity against HIV.
SI- selectivity index, ratio between toxic and effective concentration, parameter of (non) toxicity.
AE- aqueous extract.
EE- ethanolic extract.
ME- methanolic extract.
EAE- ethyl acetate extract.
RT- reverse transcriptase.
PBMC- peripheral blood mononuclear cells.
### Table 4
Some representatives of Lamiaceae family with antiviral activities against other viruses.

| Plant species       | Type of extract (with main compound(s)) | Additional comments                                                                 | References |
|---------------------|-----------------------------------------|--------------------------------------------------------------------------------------|------------|
| thyme               | EO (p-cymen and thymol)                 | • activity against HSV-1                                                            | [62]       |
| Thymus vulgaris     | EO (thymol and carvacrol)               | • activity against HSV-1                                                            | [63]       |
|                     | EO (thymol and p-cymen)                 | • activity against HSV-2                                                            | [64]       |
| Thymus capitata     | AE                                       | • activity against HSV-2                                                            | [65]       |
| Thymus linearis     | ME                                       | • activity against HSV-1                                                            | [67]       |
| Mentha × piperita   | EO (menthol and menthon)                | • activity against HSV-1 and HSV-2                                                 | [68]       |
| Mentha suaveolens   | EO (piperitenon oxide)                  | • activity against HSV-1                                                            | [69]       |
| Rosmarinus officinalis | AE                                    | • activity against HSV-2                                                            | [64]       |
| Melissa officinalis | EO (β-cubebene and β-caryophyllene)     | • activity against HSV-2                                                            | [70]       |
|                     | EO (geranial, β-caryophyllen and neral) | • activity against HSV-1 and HSV-2                                                 | [71]       |
|                     | AE, EE                                  | • activity against HSV-1                                                            | [72]       |
|                     |                                         | • no activity in rabbits (eye infection)                                           |            |
|                     | AE                                       | • activity against HSV-1                                                            | [73]       |
|                     | AE                                       | • activity against HSV-1                                                            | [74]       |
|                     |                                         | • activity against both acyclovir resistant and susceptible strains                |            |
|                     | EE                                       | • activity against HSV-2                                                            | [75]       |
|                     | cream containing extract                | • efficient in patients with recurrent herpes simplex labialis                      | [76]       |
| Ocimum basilicum    | AE, EE                                  | • activity against HSV-1 and HSV-2                                                 | [77]       |
|                     |                                         | • AE was more potent than EE                                                       |            |
| Hyssopus officinalis| EO (isopinocamphone and 1-pinocamphone) | • activity against HSV-1                                                            | [78]       |
|                     |                                         | • activity against both acyclovir resistant and susceptible strains                |            |
| Salvia officinalis  | AE, EE                                  | • activity against HSV-1                                                            | [71]       |
|                     |                                         | • EE was more potent than AE                                                      |            |
|                     | AE                                       | • no activity against HSV-2                                                        | [64]       |
|                     | EO (1,8-cineol and α-thujone)           | • activity against HSV-1                                                            | [79]       |
|                     | creams containing extract               | • efficient in patients with recurrent herpes simplex labialis                      | [80]       |
|                     |                                          | • sage, as well as sage and rhubarb mixture were both efficient                    |            |
| Satureja boliviana  | AE, EE                                  | • activity against HSV-1                                                            | [81]       |
|                     |                                         | • EE was found to be toxic                                                        |            |
| Satureja thymbra    | EO (p-cymene, α-pinene and thymol)      | • activity against HSV-1                                                            | [79]       |
| Ocimum basilicum    | AE, EE                                  | • AE was more potent than EE                                                       | [77]       |
| Plant species            | Type of extract (with main compound(s)) | Additional comments                                                                 | References |
|-------------------------|----------------------------------------|--------------------------------------------------------------------------------------|------------|
| **RNA Viruses With Envelopes**                                      |                                        |                                                                                      |            |
| **Influenza virus**                                                |                                        |                                                                                      |            |
| *Thymus linearis*         | ME                                     | • no activity against human H1N1                                                   | [67]       |
| *Melissa officinalis*     | EO (geranial and neral)                | • activity against avian H9N2                                                        | [82]       |
|                          |                                        | • synergistic effect with oseltamivir                                                |            |
| *Ocimum sanctum*          | EE                                     | • activity against human H1N1                                                       | [83]       |
| *Prunella vulgaris*       | ME                                     | • no activity against H1N1 in ovo                                                   | [84]       |
| *Thymus vulgaris*         | AE                                     | • activity against H1N1                                                             | [85]       |
| *Thymus vulgaris*         | EE                                     | • activity in ovo                                                                    | [86]       |
| *Salvia officinalis*      | AE                                     | • activity against all viruses                                                      | [64]       |
| *Rosmarinus officinalis*  | AE                                     | • activity against all viruses                                                      | [64]       |
| *Salvia officinalis*      | AE                                     | • activity against all viruses                                                      | [64]       |
| *Satureja boliviana*      | AE, EE                                | • activity against VSV                                                               | [81]       |
|                          |                                        | • EE was found to be toxic                                                           |            |
| *Ocimum basilicum*        | EO                                     | • virus sometimes used as a surrogate model for hepatitis C virus                   | [87]       |
| *Ocimum sanctum*          | ME                                     | • no activity against serotype 1                                                    | [89]       |
|                          |                                        | • high toxicity for cells                                                           |            |
| *Prunella vulgaris*       | AE                                     | • no activity against murine norovirus MNV-1                                        | [93]       |
| *Prunella vulgaris*       | AE, EE                                | • AE was more potent than EE                                                        | [91]       |
| *Salvia miltiorrhiza*     | AE, EAE                               | • no activity against these viruses                                                 | [92]       |
| **Newcastle Disease virus**                                        |                                        |                                                                                      |            |
| *Thymus vulgaris*         | EE                                     | • activity in ovo                                                                    | [86]       |
| *Salvia officinalis*      | EO (1,8-cineol and α-thujone)         | • no activity                                                                       | [79]       |
| *Satureja thymbra*        | EO (p-cymene, α-pinene and thymol)    | • no activity                                                                       | [79]       |
| *Ocimum basilicum*        | EO                                     | • virus sometimes used as a surrogate model for hepatitis C virus                   | [87]       |
| *Ocimum basilicum*        | EO (trans sabinene)                    | • no activity against serotype 1                                                    | [89]       |
| *Hyssopus officinalis*    | EO                                     | • no activity against serotype 1                                                    | [89]       |
| **SARS coronavirus**      |                                        |                                                                                      |            |
| *Salvia officinalis*      | EO                                     | • no activity                                                                       | [79]       |
| *Satureja thymbra*        | EO                                     | • no activity                                                                       | [79]       |
| *Ocimum basilicum*        | EO                                     | • no activity against serotype 1                                                    | [89]       |
| *Ocimum sanctum*          | ME                                     | • high toxicity for cells                                                           | [89]       |
| *Prunella vulgaris*       | AE                                     | • no activity against murine norovirus MNV-1                                        | [93]       |
| *Prunella vulgaris*       | AE, EE                                | • AE was more potent than EE                                                        | [91]       |
| *Salvia miltiorrhiza*     | AE, EAE                               | • no activity against these viruses                                                 | [92]       |
| **DNA Viruses Without Envelopes**                                   |                                        |                                                                                      |            |
| *Thymus mastichina*       | EO                                     | • no activity against human adenovirus serotype 2 (HAdV-2)                          | [93]       |
| *Ocimum basilicum*        | AE, EE                                | • activity against ADV-3, ADV-8, ADV-11                                             | [77]       |
| *Hyssopus officinalis*    | EO                                     | • no activity against human adenovirus serotype 2 (HAdV-2)                          | [93]       |
| **RNA Viruses Without Envelopes**                                   |                                        |                                                                                      |            |
| *Thymus mastichina*       | EO                                     | • no activity against these viruses                                                 | [92]       |
| *Origanum vulgare*        | EO                                     | • no activity against poliovirus type 1                                              | [81]       |
| *Satureja boliviana*      | AE                                     | • no activity against murine norovirus MNV-1                                        | [93]       |
| *Thymus mastichina*       | EO                                     | • activity against murine norovirus MNV-1                                            | [94]       |
Diterpene carnosic acid (Fig. 1) was found to be effective against RNA enveloped respiratory syncytial virus (RSV) with acceptable toxicity [110]. Apigenin (flavonoid aglycone) and acacetin glycosides showed weak to moderate activity against human RSV Long strain [108]. The previously mentioned saffolinolide and sageone exhibited effects against another RNA virus, VSV [107]. It is interesting to point out that the research even detected some compounds with activity against RNA non-enveloped viruses, generally viewed as more challenging for therapy. Rosmarinic acid (Fig. 1) and lisophosphates A, as single compounds from *S. miltiorrhiza*, were effective against enterovirus 71 [111]. Carvacrol (Fig. 1) (commonly found as a major compound of *O. vulgare EO*) displayed activity against non-enveloped murine norovirus [112]. Ursolic acid (Fig. 1) had excellent activity against RNA non-enveloped viruses such as Coxackievirus B1 and enterovirus 71, but also against DNA non-enveloped adenoviruses [77]. *In silico* molecular studies of various compounds from *O. sanctum* also confirmed good antiviral activity of ursolic acid [113].

**6. Activity versus toxicity**

The most important parameter that needs to be determined in antiviral testing is the minimum concentration needed for inhibition of viral replication. It is suggested that these values should be \(<100 \, \mu\text{g} \, \text{mL}^{-1}\) for extracts and EOs, and as it can be seen in Table 3, majority of plants with activity against HIV follow this rule. However, this is not the only parameter that should be used for assessment of antiviral effectiveness of different plant based products. Due to the fact that studies of antiviral activity are performed in living systems (usually cell cultures), a minimum concentration that displays (cyto)toxicity should also be reported [114]. Selectivity index (SI) represents the ratio of determined cytotoxic concentration and effective concentration. SI is a valuable indicator of effectiveness of the tested substance, and, if the compound or mixture exhibits activity in low concentrations, it is not considered useful and applicable if its SI is also low. Only values of SI higher than 4 are considered appropriate [114,115]. For example, carnosic acid was toxic for tested cells, even though it displayed potent activity against HIV integrase *in vitro* [116]. Compounds salvianolic acids D and E, isolated from different *Salvia* species, were proven to be extremely effective *in vitro* against HIV-1 integrase.

| Plant species               | Type of extract (with main compound(s)) | Additional comments                                                                                     | References |
|-----------------------------|----------------------------------------|--------------------------------------------------------------------------------------------------------|------------|
| *Hyssopus officinalis*      | EO                                     | • no activity against murine norovirus MNV-1                                                        | [93]       |
| *Mentha haplocalyx*         | AE                                     | • activity against coxsackie virus A16                                                              | [94]       |
| *Mentha haplocalyx*         | AE                                     | • inhibition of inflammatory response of cell culture during viral replication                        |            |
| *Ocimum basilicum*          | AE, EE                                | • activity against coxsackie virus B1                                                                | [77]       |
| *Salvia miltiorrhiza*       | AE, EAE                               | • no activity against coxsackie virus A16                                                          | [92]       |
| *Mentha haplocalyx*         | AE                                     | • no activity against enterovirus 71                                                                | [94]       |
| *Ocimum basilicum*          | AE, EE                                | • activity against enterovirus 71                                                                   | [77]       |
| *Salvia miltiorrhiza*       | AE, EAE                               | • activity against three genotypes of enterovirus 71                                                | [92]       |
However, they were not further evaluated for antiviral effects due to their toxicity [117]. Some plants’ extracts e.g. EE of *Salvia triloba* [50], EE of *Satureja boliviana* [81], ME of *Ocimum sanctum* [89], commercially available rosemary extract and a mixture of Provençal Herbs (containing rosemary, sage, thyme and oregano) [51] were proven as toxic, so estimation of their anti(retro)viral activity was not possible.

7. **Studying mechanism of antiviral activity**

7.1. **Time-of-addition (T-o-A) studies**

A notable number of studies reviewed in this paper have also tried to detect the exact M-o-A of IS. This was achieved through the time-of-addition (T-o-A) study, which is comprised of assays with different procedures of addition of IS, viral suspension and cell cultures [48, 54–56, 62–64, 66, 68, 69, 71, 73, 74, 77, 82, 87, 88, 91, 92, 94, 104, 106, 112]. Based on the highest activity in a certain assay, a conclusion about the exact type of M-o-A can be derived (Fig. 2). Generally, four assays for investigating antiviral effects of different mixtures and substances are in use:

1. Pretreatment of the cell culture- IS is incubated with a cell culture, and after a certain time period, a viral suspension is added. In this case, the results show whether the IS was able to penetrate inside the cells and manifest its activity.
2. Pretreatment of the virus- A viral suspension is incubated together with the IS. After the incubation, the suspension is rinsed of substance and inoculated into the cell culture. Activity in this assay indicates direct activity towards the virus and its structures, e.g. the envelope.
3. Adsorption- The viral suspension and IS are added simultaneously into cell cultures. This assay indicates activity towards structures responsible for viral attachment and/or penetration of virus into the cells.
4. Intracellular replication - IS is added during viral replication inside the cells. Substances showing activity in this assay are able to affect later stages of the viral life cycle [71].

In the case of different Lamiaceae species, the majority of IS, both extracts and single compounds, displayed activity in cases of pretreatment of viral particles. This resulted in strong and dose-dependent inhibition of viral infectivity. Several experiments suggested that viral envelope is the target site for ISs, as it is confirmed by comparing antiviral activities against enveloped and non-enveloped viral species. This is not a strict rule - some IS demonstrated activity against non-enveloped viruses [112] and there was no activity against some enveloped viruses [94].

Activity in cases of virus pretreatment does not exclude activity in the assay of adsorption inhibition; as it is possible that IS displays effects in a short period of time during simultaneous addition of IS and of viral particles into cell cultures. However, minor activity recorded in adsorption inhibition demonstrates that IS can affect both the viral envelope and other structures responsible for viral attachment and/or penetration into target cells.

Some research provided evidence that ISs had no lytic effects towards viral particles. These papers demonstrated that the
integrity of particles was maintained after treatment with AEs of peppermint, lemon balm, common sage [48] and self-heal [56,91] and EO of oregano and carvacrol [112].

Interestingly, a drastic change in HIV virion density after exposure to AEs of lemon balm and peppermint was detected [48]. Researchers presumed that this was the consequence of ISs interactions with macromolecules in viral structures, responsible for normal viral integrity and infectivity, although this was not confirmed with experiments. The change of density was not recorded in the case of HIV [56] or in the equine infectious anemia virus [91] treated with self-heal.

As it can be seen in Table 4, AEs with different main compounds were also investigated for antiviral effects. Usually, only two or three compounds are present in higher concentrations and considered responsible for the activity. Main compounds in EO are usually determined by genetics, but different ecological factors could affect their concentration rather than the method used for isolation [119].

The effect of different main compounds in EO can be illustrated in the example of lemon balm. First EO with β-cubebene and β-carophyllene as major compounds exhibited effects in cases of cell pretreatment with IS [70], while EO containing mainly gera- nial, β-carophyllene and neral achieved effects when HSV-1 and HSV-2 viruses were pretreated and effects were absent in other T-O A studies [71]. This leads to a conclusion that different compounds affect different stages of viral life cycle and achieve effect through different mechanisms.

7.2. Comparison with conventional drugs

Researchers often compare natural products with conventional drugs, commonly included as positive control- this provides information on strength of activity of a natural product. Another possible reason for these assays is to determine whether IS has the same M-o-A.

In the case of HIV, there is frequent comparison of activity against RT (Table 3). This unique and specific HIV enzyme is one of the key targets for conventional therapy, so it is no surprise that researchers tried to detect plants with activity against this enzyme. However, in HIV’s life cycle, several other structures can also be targets, so natural products are also compared with drugs displaying other M-o-A. This can be illustrated in the example of Prunella vulgaris (Xia Ku Cao, self-heal), a plant frequently used in Traditional Chinese Medicine. Besides activity against RT (which resembles the M-o-A of nucleoside RT inhibitors), AE demonstrated activity against enzymes integrase and protease, and inhibition of interaction of HIV gp120 and gp41 with corresponding structures on target cells, similar to activities of integrase inhibitors, protease inhibitors, co-receptor antagonists and fusion inhibitors, respectively (Tables 1 and 3), thus mimicking M-o-A of antiretroviral drugs. As it was previously mentioned, some isolated compounds were also found to have a M-o-A similar to conventional drugs.

8. Studying activity in cases of chronic HIV infection

Besides simulating acute infection, in the case of HIV it is also important to investigate the activity of compounds and natural products in chronic infection. This is achieved through simulation in an in vitro assay with non-infected cells and cells chronically infected with HIV (with cell lines being of the same or different origin). Techniques of these assays are versatile, but the general principle is to co-culture both cell cultures in the presence of IS, determining whether IS can prevent virus spreading to non-infected cells [120]. Some of the examined Lamiaceae species (lemon balm, self-heal, and some representatives from genera Thymus, Mentha, Origanum, Ocimum, Salvia and Satureja) exhibited this activity (Table 3). However, the lack of effect may correspond with previously detected substance activity only in early stages of viral life cycle.

9. Potential position in the therapy

Extracts and AOs can also be compared for their activity against different viral strains, both susceptible and resistant to conventional drugs. This was most frequently tested on herpes simplex viral strains, as resistance to acyclovir is a therapeutic problem. Several Lamiaceae representatives (thyme, peppermint, lemon balm, self-heal and hyssop) were tested simultaneously against acyclovir resistant and acyclovir susceptible strains of HSV. Interestingly, they were equally susceptible to used extracts [63,68,74]. Besides this, lemon balm was proven to be efficient in cases of HIV strains resistant to enfuvirtide, fusion inhibitor [48].

Potential synergism with conventional drugs could result in new recommendations of plant application with antiviral therapy. In revised literature, EO of Mentha suaveolens showed a synergistic effect with acyclovir against HSV-1 [69] and EO of lemon balm showed synergism with oseltamivir against avian H9N2 influenza virus [82]. In both cases, sub-optimal doses of drugs were enhanced with EOs, resulting in good antiviral activities.

Both of the previous cases (comparison of strains and synergism) have led to the conclusion that natural products can exhibit different M-o-A than conventional drugs. Still, idea of combining drugs (both conventional and herbal) with different M-o-A could be a good therapeutic approach. This is in accordance with the main idea of cART- use of several drugs results in good activity against virus, with decreased side effects and toxic properties of drugs.

10. The “non- in vitro” studies and future considerations

As previously stated, the majority of studies are conducted in vitro. This is the main type of investigation due to convenience and lower cost of studies. However, concerning HIV, it is completely understandable from an ethical point of view why these in vitro studies are the only type of conducted studies, to the best of our knowledge. Still, some other types of investigations are being attempted, in order to get valid results, possibly applicable to patients.

Some papers investigated activity in ovo [84,86]. This approach is presumably conducted in order to simulate natural living cells (rather than cell cultures), giving a more accurate answer to the question- Does IS show activity and lack of toxicity at the same time? Animal studies are not widely accepted, and only study by Dimitrova et al. [72] demonstrated a lack of activity of lemon balm against HIV-1 when it was tested in rabbits, in provoked eye infection.

Thyme and hyssop preparations were estimated for their ability to increase the number and/or viability of peripheral blood mononuclear cells (PBMCs) of healthy donors [47,97]. A study by Feng et al. [57] included healthy volunteers who had taken self-heal for a week. These individuals had a reduced level of chemokine co-receptors in T cells, one of key structures in the HIV life cycle, and one of therapeutic targets. The positive outcome in these ex vivo and in vivo studies suggest modulatory effects of these plants towards immunity. This also suggest that antiviral activity can be indirect, rather than having direct effects (e.g. targeting viral envelope) as it is seen in in vitro studies.

Finally, some plants were studied for their activity in patients, in assays testing pharmaceutical formulations for local application in cases of recurrent herpes labialis. Commercially available cream containing extract of lemon balm was proven to be efficient in the treatment of this sometimes complex problem. The cream
was able to reduce the intensity of complaints, number of blisters and affected area size in patients, especially if the application is started immediately after the onset of prodromes [76]. Also, creams containing sage extract, as well as sage and rhubarb mixture were proven to be efficient in the treatment of herpes labialis in patients. Application of these creams reduced the symptoms and duration of viral episodes [80]. These investigations of antiviral activity in some patients and their positive outcomes suggest that application of adequate formulations confirmed antiviral activity which was previously noted only in vitro. Local application is an effective type of treatment which may be advised to patients in addition to conventional therapy, reducing side effects of viral diseases.

As Lamiaceae plants are demonstrated to be effective in vitro, possible ideas for future researches would be to test these plants in patients with viral infections. The starting points would be to select a plant (possibly by using informations of effective concentrations and SIs) and adequate form (as it is previously explained, AE appears to be the most promising). Use of the most abundant compounds in products (some suggested in the previous text) is an even more precise approach to investigation. Application of plants should, however, be carefully monitored. Although the plants generally have many potential beneficial effects, they also have potential to cause interactions with antiretroviral and other drugs, resulting in a drastic increase or decrease of drug concentrations in patients, leading to toxicity or therapeutic failure. However, in cases of HIV, it is believed that prolonged exposure to drugs (not exceeding therapeutic concentrations) can be positive for patients, as it prevents selection of resistant strains and possibly decreases doses of conventional drugs, together with their side effects [121]. With careful monitoring of drug concentration, management of simultaneous use of conventional therapy and phytopharmacy should not be a problem.

11. Conclusions

Numerous in vitro screenings pointed to notable antiretroviral properties of different species of the Lamiaceae family. The effect is generally strong and dose-dependent, and the most likely mechanism of activity is direct effect against outer structures (primarily viral envelope) consequentially disabling viral attachment to target cells. Several other experiments with local therapeutic forms gave encouraging results, demonstrating potential of Lamiaceae plants as adjunctive therapy. Further clinical trials could give final conclusions on antiviral activity and the application on patients.

Conflicts of interest

The authors declare that they have no conflict of interest.

Acknowledgements

This work was supported by The Provincial Secretariat for Science and Technological Development of Vojvodina (grant number 114-451-2730/2016-03) and The Ministry of Education, Science and Technological Development, Republic of Serbia (grant number OI 172058).

References

[1] E.J. Arts, D.J. Hazuda, HIV-1 antiretroviral drug therapy, Cold Spring Harb. Perspect. Med. 2 (4) (2012) a007161, http://dx.doi.org/10.1101/cshperspect.a007161.
[2] T. Hawkins, Understanding and managing the adverse effects of antiretroviral therapy, Antiviral Res. 85 (1) (2010) 201–209.
[3] K.J. Cortez, F. Maldarelli, Clinical management of HIV drug resistance, Viruses 3 (4) (2012) 347–378.
[4] UNAIDS (Joint United Nations Programme on HIV/AIDS), Global AIDS Update 2016, 2016, http://www.unaids.org/en/media/unaids/contentassets/documents/epi_rap/GlobalAIDSUpdate2016_en.pdf. (Accessed 5 March 2017).
[5] S.A. Jassim, M.A. Naji, Novel antiviral agents: a medical plant perspective, J. Appl. Microbiol. 95 (3) (2003) 412–427.
[6] M. Mukhtar, M. Ashraf, M. Ahmad, R.J. Pomerezant, B. Wiegala, Z. Parveen, Antiviral potentials of medicinal plants, Virus Res. 131 (2) (2008) 111–120.
[7] R. Naithani, L.C. Huma, L.E. Holland, D. Shukla, D.L. McCormick, R.G. Mehta, R.M. Morarity, Antiviral activity of phytochemicals: a comprehensive review, Mini Rev. Med. Chem. 8 (11) (2008) 1106–1133.
[8] Y. Jin, X. Wang, Z. Li, Z. Jiang, H. Guo, Z. Liu, L. Xu, Survival of AIDS patients treated with traditional Chinese medicine in rural central China: a retrospective cohort study, 2004–2012. Evid. Based Complement. Altern. Med. 2015 (2015) 282819, http://dx.doi.org/10.1155/2015/282819.
[9] Z.B. Liu, J.P. Yang, L.R. Xu, Effectiveness and safety of traditional Chinese medicine in treating acquired immune deficiency syndrome: 2004–2014, Infect. Dis. Poverty 4 (2015) 59, http://dx.doi.org/10.1186/s40129-015-0003-6.
[10] W. Zou, J. Wang, Y. Liu, Effect of traditional Chinese medicine for treating human immunodeficiency virus infections and acquired immune deficiency syndrome: boosting immune and alleviating symptoms, Chin. J. Integr. Med. 22 (1) (2016) 3–8.
[11] Y. Wang, F. Jin, W. Zhang, S. Suo, Long-term survival of AIDS patients treated with only traditional Chinese medicine, AIDS Res. Hum. Retroviruses 33 (2) (2017) 90–92.
[12] H.L. Zhao, C.Z. Sun, W.P. Jiang, Z.K. Dai, W.X. Shi, K.K. Yang, X.J. Mu, X.X. Zhang, Y. Sui, Eight-year survival of AIDS patients treated with Chinese herbal medicine, Am. J. Chin. Med. 42 (2) (2014) 274–298.
[13] R. Ramasubramania Raja, Medicinally potential plants of Labiatae (Lamiaceae) family: an overview, Res. J. Med. Plants 6 (3) (2012) 203–213.
[14] R. Amber, M. Adnan, A. Tarig, S. Mussarat, A review on antiviral activity of the Himalayan medicinal plants traditionally used to treat bronchitis and related symptoms, J. Pharm. Pharmacol. 69 (2) (2017) 109–122.
[15] S. Jarić, M. Mitrović, P. Pavlović, Review of ethnobotanical, phytoremediation, and pharmacological studies of Thymus serpyllum L. (Lamiaceae), Altern. Med. (2015) 101978, http://dx.doi.org/10.1155/2015/101978.
[16] A. Begum, S. Sandhya, S. Shafath Ali, K.R. Vinod, S. Reddy, D. Banji, An in-depth review on the medicinal flora Rosmarinus officinalis (Lamiaceae), Acta Sci. Pol. Technol. Aliment. 3 (2) (2013) 61–73.
[17] World Health Organisation (WHO), WHO Traditional Medicine Strategy: 2014-2023, 2013, http://apps.who.int/iris/bitstream/10665/245451/1/ 9789241569090_eng.pdf?ua=1. (Accessed 5 November 2017).
[18] V. Prashanti Reddy, K. Ravi Viral, P.V. Varsha, S. Satyan, Review on Aromat. Plants 3 (3) (2014) 164, http://dx.doi.org/10.4172/2167-0412.1000164.
[19] M. Blumenthal (Ed.), The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines, American Botanical Council, Austin, Texas, 1998.
[20] European Medicines Agency (EMA), Thyme Thymus vulgaris L. and Thymus serpyllum L., EMEA/2014/001131-001162. (Accessed 6 November 2017).
[21] World Health Organisation (WHO), WHO Monographs on Selected Medicinal Plants, vol. 1, 1990.
[22] D.L. McKay, J.B. Blumberg, A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.), Phytother. Res. 20 (8) (2006) 619–633.
[23] European Medicines Agency (EMA), European Union Herbal Monograph on Mentha x piperita L., Folium, EMA/HMPC/572705/2014. <http://www.ema. europa.eu/docs/en_GB/document_library/Herbal__monograph/2017/02/WC500221959.pdf>. (Accessed 6 November 2017).
[24] World Health Organisation (WHO), WHO Monographs on Selected Medicinal Plants, vol. 2, 2004.
[25] European Medicines Agency (EMA), Community Herbal Monograph on Rosmarinus officinalis L., Aetheroleum, EMA/HMP/C/215453/2009. <http:// www.ema.europa.eu/docs/en_GB/document_library/Herbal__monograph/2011/01/WC500101493.pdf>. (Accessed 6 November 2017).
[26] World Health Organisation (WHO), WHO Monographs on Selected Medicinal Plants, vol. 4, 2009.
[27] A. Shakeri, A. Sahebkar, B. Javadi, Melissa officinalis L.- a review of its traditional uses, phytochemistry and pharmacology. J. Ethnopharmacol. 188 (2016) 204–228.
[28] European Medicines Agency (EMA), Melissa Leaf Melissa officinalis L., Folium, EMA/HMP/310761/2013. <http://www.ema.europa.eu/docs/en_GB/document_library/Herbal__monograph/2014/06/WC500168590.pdf>. (Accessed 6 November 2017).
[29] S. Chishti, Z.A. Kaloo, P. Sultan, Medicinal importance of genus Origanum: a review, J. Pharmacogn. Phytochem. 5 (10) (2015) 170–177.
[30] European Medicines Agency (EMA), European Union Herbal Monograph on Origanum majorana L. Herba, EMA/HMP/166517/2015. <http://www.ema. europa.eu/docs/en_GB/document_library/Herbal__monograph/2016/02/WC500201951.pdf>. (Accessed 6 November 2017).
[31] A.K. Pandey, P. Singh, N.N. Tripathi, Chemistry and bioactivities of essential oils of some Ocimum species: an overview, Asian Pac. J. Trop. Biomed. 4 (9) (2014) 682–694.
3141–3150.

balm

117–127.

Antimicrobial

Boˇzin,

Crops

Bozin,

Carovi´c-Stanko,

1988)

Yao,

Oh,

intestine

Spencer,

in

J.

in

Aqueous

Inhibition

of

Elaeophorbia

(1)

and

volatile

(3)

comparison

the

composition

of

L.,

crude

of

a

in

rosemary

Clausena

Kageyama,

and

integrated

by

aqueous

and

methanol

extracts

of

Chinese

medicinal

herbs,

Life

Sci.

60

(23

(1997)

PL345–351.

T.K. Au, T.T. Lam, T.B. Ng, W.P. Fong, D.C. Wan, A Comparison of human immunodeficiency virus type 1 inhibition by partially purified aqueous extracts of Chinese medicinal herbs, Life Sci. 67 (23) (2000) 1779–1791.

W. Krei, M.H. Kaplan, J. Freeman, D.K. Sun, P.S. Sarin, Inhibition of HIV replication by Hostos niveaus extracts, Antiviral Res. 14 (6) (1990) 331–342.

A. Astani, J. Reichling, P. Schnitzler, Comparative study on the antiviral activity of selected monoterpene derivatives from essential oils, Phytother. Res. 24 (5) (2010) 673–679.

P. Schnitzler, C. Koch, J. Reichling, Susceptibility of drug-resistant clinical herpes simplex virus type 1 strains to essential oils of ginger, thyme, hyssop, and sandalwood, Antimicrob. Agents Chemother. 51 (7) (2007) 1859–1862.

C. Koch, J. Reichling, J. Schneele, P. Schnitzler, Inhibitory effect of essential oils against herpes simplex virus type 2, Phytomedicine 15 (1–2) (2008) 71–78.

S.I. El-Awady, T. Essam, A. Hashem, A.H.A. Bosenia, A.F. Mohmed, Assyess of antiviral activity of lavender (Lavandula spp.) crude oil against Rna and Dna virus models using cell-culture: in vitro study, World J. Med. Sci. 11 (1) (2014) 111–119.

R. Boubadian-Elandaloussi, M. Metem-Toujani, B. Kaabi, L. Larbi, M.F. Diouani, M. Gharbi, H. Akkaï, F. Bouza, Non-erythocytic Treatment of cytokine extracts prevent Bovine herpesvirus-1 infection in cell cultures, BMC Vet. Res. 10 (2014) 231, http://dx.doi.org/10.1186/1746-6148-10-231.

L. Caviglioli, D. Rajabi, R. Mehrali, T. Khojasteh, S. Gharbati, A.M. Golestaneh, M.B. Gisvai, M. Karmacharya, M. Hipper, U. Lindequeit, Antiviral activity of some plants used in Nepalese traditional medicine, Evid. Based Complement. Altern. Med. 6 (4) (2009) 517–522.

A. Schulmacher, J. Reichling, P. Schnitzler, Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro, Phytomedicine 10 (6–7) (2003) 504–510.

L. Civielli, S. Panella, M.E. Marocci, A. De Petris, S. Garzoli, F. Pepi, E. Valva, R. Ragno, L. Nencioni, A.T. Alamar, L. Angioldella, In vitro inhibition of herpes simplex virus type 1 replication by Menta suaveolens essential oil and its main piperitone oxide, Phytochemistry 21 (6) (2008) 857–865. 8. A. Allahverdypour, N. Duran, M. Ozoguzen, S. Kolta, Antiviral activity of the volatile oils of Melissa officinalis L. against Herpes simplex virus type 2, Phytochemistry 11 (7–8) (2004) 657–661.

P. Schnitzler, A. Schulmacher, A. Astani, J. Reichling, Melissa officinalis oil affects infectivity of enveloped herpesviruses, Phytomedicine 15 (9) (2008) 734–740.

Z. Dimitrova, B. Dimov, N. Manolova, S. Pancheva, D. Ilieva, S. Shishkov, Antiviral effects of Melissa officinalis L. extracts, Acta Microbiol. Bulg. 29 (1993) 65–72.

A. Astani, J. Reichling, P. Schnitzler, Melissa officinalis extract inhibits attachment of herpes simplex virus in vitro, Chemotherapy 58 (1) (2012) 70–77.

A. Astani, M.H. Navid, P. Schnitzler, Attachment and penetration of acyclovir-resistant herpes simplex virus are inhibited by Melissa officinalis extract, Phytother. Res. 28 (10) (2014) 1547–1552.

G. Mazzanti, L. Battinelli, C. Pompoo, A.M. Serrilli, R. Rossi, I. Saufillo, F. Mengoni, V. Vullo, Inhibitory activity of Melissa officinalis L. extract on Herpes simplex virus type 2 replication, Nat. Prod. Res. 22 (16) (2008) 1435–1440.

R. Roychev, R.G. Allen, S. Dundarov, Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis, Phytomedicine 6 (4) (1999) 225–230. 15. L.C. Chiang, L.T. Ng, P.W. Chong, W. Chiang, C.C. Lin, Antiviral activities of extracts and selected pure constituents of Ocinum basilicum, Clin. Exp. Pharmacol. Physiol. 32 (10) (2005) 811–816.

P. Schnitzler, S. Noltemper, F.C. Stintzing, J. Reichling, Comparative in vitro study on the anti-herpetic effect of phytochemically characterized aqueous and ethanol extracts of Melissa officinalis grown at two different locations, Phytomedicine 15 (1–2) (2008) 62–70.

M.R. Loizzo, A.M. Saab, R. Tundis, G.A. Statti, F. Menichini, I. Lamproti, R. Gamberi, J. Cinat, H.W. Doert, Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species, Chem. Biodivers. 5 (3) (2008) 461–470.

R. Saller, S. Buechi, R. Meyrat, C. Schmidhauser, Combined herbal preparation for topical application of Herpes labialis in laboratory and clinical settings, Komplementarmed. Klass. Naturheilkd. 8 (6) (2001) 373–382.

M.J. Abd, P. Bermejo, E. Gonzales, I. Iglesias, A. Irurzun, L. Carrasco, Antiviral activity of Bolivian plant extracts, Gen. Pharmacol. 32 (4) (1999) 499–503.

G. Pourghasemi, H. Nili, A. Moattari, A. Mohammad, A. Iraqi, Antiviral activity of the oseltamivir and Melissa officinalis L. essential oil against avian influenza A virus (H9N2), VirusDisease 27 (2) (2016) 170–178.
Fang, virus potent

Isolation L.I. Tian, Rezatofighi, Ncube, A.J. foot, integrase C. (2016)

of non-toxic A.J. Alves, Biophys. from Mohammadi, X. Mbemba, X. (2014)

extract an anti-HIV the origin: component 5053–5056. Complement.

against Influenza on http://dx.doi.org/10.1186/1743-422X-10-303.

against an HSV-2. Influenza Res. 75 (2015) 127–133.

against carvacrol against murine norovirus, J. Appl. Microbiol. 116 (5) (2014)

M. Alhazmi, Molecular docking of selected phytocompounds with H1N1 proteins, Bioinformation 11 (4) (2015) 196–202.

P. Cos, A.J. Viltenick, D.V. Berghe, L. Maes, Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’, J. Ethnopharmacol. 106 (3) (2006) 290–302.

M. Amoros, C.M. Simões, L. Girre, F. Sauvagner, M. Cormier, Synergistic effect of flavones and flavonoids against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis, J. Nat. Prod. 55 (12) (1992) 1732–1740.

A. Paril, B. Strukiel, M. Renko, V. Turk, M. Pukl, A. Umek, B.D. Korant, Inhibitory effect of carnosic acid on HIV-1 protease in cell-free assays, J. Nat. Prod. 56 (8) (1993) 1426–1430, Erratum in: J. Nat. Prod. 57 (4) (1994) 552.

C. Queffelec, F. Baille, G. Mbemba, J.F. Mouscardet, S. Hayes, Z. Debyser, M. Witvrouw, P. Cotelle, Synthesis and antiviral properties of some polyflavones related to Salvia genus, Bioorg. Med. Chem. Lett. 18 (16) (2008) 4736–4740.

R. Roskoski Jr, Guidelines for preparing color figures for everyone including the colorblind, Pharmacol. Res. 119 (2017) 240–241.

M.T. Islam, A.M. da Mata, R.P. de Aguiar, M.F. Paz, M.V. de Alencar, P.M. Ferreira, A.A. de Carvalho Melo–Cavalcante, Therapeutic potential of essential oils focusing on diterpenes, Phytother. Res. 30 (9) (2016) 1420–1444.

D. Daelemans, R. Pauwels, E. De Clercq, C. Pannecoque, A time–of–drug addition approach to target identification of antiviral compounds, Nat. Protoc. 6 (6) (2011) 925–933.

M. Lamorde, P. Byakika–Kwebika, C. Merry, Pharmacokinetic interactions between antiretroviral drugs and herbal medicines, Br. J. Hosp. Med. (Lond.) 73 (3) (2012) 132–136.